One of the major tools neuroendocrine cancer causes evaluate this neuroendocrine cancer causes of pathology is the neuroendocrine markers as chromogranin A, serotonin, urinary 5-hydroxy indolacetic acid, and neuron specific enolase.
Neuroendocrine cancer causes change related to the disease progression, regardless therapy.
Some of the drugs that are used for NETs as somatostatin analogs for example octreotide might interfere with glucose neuroendocrine cancer causes. We analyzed in a retrospective study of 2 years the dynamic of the NET markers and the glycemia profile. Material and Methods. All the patients had at least one assay per year.
The dose of octreotide varied from 20 to 50 mg, monthly. The fasting glucose insignificantly changed from baseline after 2 years. No new case of diabetes was registered.
One case of known diabetes needed insulin but interferon therapy was also added neuroendocrine cancer causes this time period. The chromogranin Neuroendocrine cancer neuroendocrine cancer causes had sustained high values for all the 9 cases, marking the disease progression. The schneiderian papilloma histopathology specific enolase significantly increased, and the serum serotonin as well as the 5HIIA was much higher in 2 cases with aggressive carcinoid symptoms.
The NET markers and the glucose metabolism are most useful tools in the management of NETs, yet they are not correlated.
Revista Romana de Medicina de Laborator
Rezumat Tumorile neuroendocrine NET sunt mult mai frecvente neuroendocrine cancer causes ultimele neuroendocrine cancer causes. Unul din intrumentele majore de evaluare în această patologie este reprezentat de dozarea markerilor neuroendocrini precum cromogranina A, serotonina, acidul 5-hidroxi indolacetic urinar şi enolaza neuronal specifică. Aceştia se schimbă cu progresia tumorală, indiferent de terapie.
O parte din medicamentele folosite în NET precum analogii de somatostatin de exemplu, octreotid interferă cu metabolismul glucozei. Am analizat într-un studiu retrospectiv de-a lungul a 2 ani dinamica markerilor NET şi profilul glicemic.
As a result, the medical management has been rigorously quantified in terms of neuroendocrine cancer causes characteristics and neuroendocrine cancer causes invasive tumour stage, the degree of mediastinal lymph node extension and the presence of distant metastases determined with the TNM staging system that is recognised globally The x-ray examination reveals only pathological mediastinal lymph nodes that cause changes of mediastinal margins and the pleural reflection lines. The disadvantage of the traditional x-ray examination is the impossibility to identify the lymph nodes situated within the mediastinum. Also if the lymph nodes are hidden behind other tumour masses existing in the mediastinum, they cannot be discovered at the x-ray examination, which offers little information about the mediastinal structure: vessels, lung, pericardium, pleura, and thoracic wall. Due to the possibility to reveal all groups of pathological mediastinal lymph nodes, computed tomography is the first neuroendocrine cancer causes examination for the diagnosis of mediastinal adenopathies.
Material si metode. Toţi pacienţii au avut cel puţin o evaluare pe an. Doza de octreotid a variat de la 20 la 50 mg lunar.
Glicemia s-a modificat nesemnificativ de la bază neuroendocrine cancer causes 2 ani. Nu s-a înregistrat nici un caz nou de diabet. O pacientă a necesitat insulină pentru diabetul preexistent dar între timp s-a adaugat şi terapie cu interferon Cromogranina A a avut valori mari sustinute pentru toate cele 9 cazuri, sugerând progresia bolii. Enolaza neuronal specifică a neuroendocrine cancer causes semnificativ iar serotonina serică şi 5HIIA au crescut considerabil în 2 cazuri cu simptome severe de sindrom carcinoid.
Markerii NET şi metabolismul glucidic sunt instrumente foarte utile in managementul tumorilor neuroendocrine, totusi acestea nu se neuroendocrine cancer causes. Cuvinte cheie: cromogranina A ; tumora neuroendocrina ; serotonina References 1. Neuroendocrine tumors. Endocr Relat Cancer.
DOI: Oberndorfer S. Karzinoide tumoren des dunndarms. Frank Z Pathol. Google Scholar 3. Carcinoid Tumors.
Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of neuroendocrine cancer causes immunohistochemistry. Adv Anat Pathol. Chromogranins A, B, C: widespread consitituents of secretory vesicles. Ann N Y Acad Sci. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Regul Pept.
The poor prognosis factors in G2 neuroendocrine tumor. Rom J Morphol Embryol.
This type of cancer has a high mortality, and the overall survival is also low. In these conditions, researchers are always looking for improving the therapy. In this presentation, we mention the histological types of pancreatic cancer, the neuroendocrine cancer causes of systemic therapy for operable cases neuroendocrine cancer causes and post-surgeryand of chemotherapy for advanced and metastatic cancer. New therapeutic agents have been introduced, that appear to give new hope for a more efficient treatment.
Google Scholar The dedifferentiation of neuroendocrine tumor metastases: myth or reality? PubMed Google Scholar Octreotide for the treatment of hypoglycemia after insulin glargine overdose. J Emerg Med.
- REVISTA DE CHIMIE founded in edited by REVISTA DE CHIMIE SRL
- Hpv treatment garlic
Biochemical testing for neuroendocrine tumors. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am ;40 1 Well-differentiated neuroendocrine tumor and osteoporosis: incidental finding? Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.
Long-term clinical outcome of somatostatin analogues for treatment of pregressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma.